Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL6 | P05231 | 8/20 | 0.82 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.35 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.32 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.32 |
| ▸ | APAF1 | O14727 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4134613 | 0.96 | IL6 (0.84) | IL6GRIN1GRIN2BPLA2G7HTR2C | |
| SCHEMBL20344621 | 0.94 | IL6 (0.83) | IL6MDM2PLA2G7HTR2CMEN1 | |
| SCHEMBL4581342 | 0.94 | IL6 (0.84) | IL6MDM2GRIN1GRIN2BPLA2G7 | |
| SCHEMBL1918700 | 0.93 | IL6 (0.80) | IL6MDM2GRIN1GRIN2BPLA2G7 | |
| SCHEMBL20344741 | 0.93 | IL6 (0.81) | IL6PLA2G7HTR2C | |
| SCHEMBL4148322 | 0.93 | IL6 (0.77) | IL6PLA2G7HTR2C | |
| SCHEMBL20344632 | 0.93 | IL6 (0.81) | IL6MDM2PLA2G7HTR2C | |
| SCHEMBL4582012 | 0.92 | IL6 (0.79) | IL6GRIN1GRIN2BPLA2G7HTR2C | |
| SCHEMBL18573561 | 0.92 | IL6 (0.81) | IL6GRIN1GRIN2BPLA2G7SYK | |
| SCHEMBL20344687 | 0.92 | IL6 (0.88) | IL6MDM2GRIN1GRIN2BPLA2G7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10435379-B2 | [4-(1,3,3-trimethyl-2-OXO-3,4-dihydro-1H-quinoxalin-7-yl)phenoxy]ethyloxy compound or salt thereof | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2019-10-08 | — | — | US | disclosed |
| US-10435379-B2 | [4-(1,3,3-trimethyl-2-OXO-3,4-dihydro-1H-quinoxalin-7-yl)phenoxy]ethyloxy compound or salt thereof | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2019-10-08 | — | — | US | disclosed |
| US-20190106393-A1 | [4-(1,3,3-TRIMETHYL-2-OXO-3,4-DIHYDRO-1H-QUINOXALIN-7-YL)PHENOXY]ETHYLOXY COMPOUND OR SALT THEREOF | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2019-04-11 | — | — | US | disclosed |
| US-20190106393-A1 | [4-(1,3,3-TRIMETHYL-2-OXO-3,4-DIHYDRO-1H-QUINOXALIN-7-YL)PHENOXY]ETHYLOXY COMPOUND OR SALT THEREOF | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2019-04-11 | — | — | US | disclosed |
| US-10189796-B2 | [4-(1,3,3-trimethyl-2-oxo-3,4-dihydro-1H-quinoxalin-7-yl)phenoxy]ethyloxy compound or salt thereof | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2019-01-29 | — | — | US | disclosed |
| US-10189796-B2 | [4-(1,3,3-trimethyl-2-oxo-3,4-dihydro-1H-quinoxalin-7-yl)phenoxy]ethyloxy compound or salt thereof | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2019-01-29 | — | — | US | disclosed |
| US-20180244633-A1 | [4-(1,3,3-TRIMETHYL-2-OXO-3,4-DIHYDRO-1H-QUINOXALIN-7-YL)PHENOXY]ETHYLOXY COMPOUND OR SALT THEREOF | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2018-08-30 | — | — | US | disclosed |
| EP-3342768-A1 | [4-(1, 3, 3-TRIMETHYL-2-OXO-3, 4-DIHYDRO-1H-QUINOXALIN-7-YL) PHENOXY]ETHYLOXY COMPOUND OR SALT THEREOF | Santen Pharmaceutical Co., Ltd. (JP) | 2018-07-04 | — | — | EP | disclosed |
| EP-3342768-A1 | [4-(1, 3, 3-TRIMETHYL-2-OXO-3, 4-DIHYDRO-1H-QUINOXALIN-7-YL) PHENOXY]ETHYLOXY COMPOUND OR SALT THEREOF | Santen Pharmaceutical Co., Ltd. (JP) | 2018-07-04 | — | — | EP | disclosed |
| WO-2017034006-A1 | [4-(1, 3, 3-TRIMETHYL-2-OXO-3, 4-DIHYDRO-1H-QUINOXALIN-7-YL) PHENOXY]ETHYLOXY COMPOUND OR SALT THEREOF | 参天製薬株式会社 | 2017-03-02 | — | — | WO | disclosed |
| US-8975256-B2 | 1,2,3,4-tetrahydroquinoxaline compounds having glucocorticoid receptor binding activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2015-03-10 | — | — | US | disclosed |
| US-8975256-B2 | 1,2,3,4-tetrahydroquinoxaline compounds having glucocorticoid receptor binding activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2015-03-10 | — | — | US | disclosed |
| US-8551991-B2 | 1,2,3,4-tetrahydroquinoxaline derivative having glucocorticoid receptor binding activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-10-08 | — | — | US | disclosed |
| US-8551991-B2 | 1,2,3,4-tetrahydroquinoxaline derivative having glucocorticoid receptor binding activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-10-08 | — | — | US | disclosed |
| EP-2151436-B1 | NOVEL 1,2,3,4-TETRAHYDROQUINOXALINE DERIVATIVE WHICH HAS, AS SUBSTITUENT, PHENYL GROUP HAVING SULFONIC ACID ESTER STRUCTURE OR SULFONIC ACID AMIDE STRUCTURE INTRODUCED THEREIN AND HAS GLUCOCORTICOID RECEPTOR-BINDING ACTIVITY | SANTEN PHARMACEUTICAL CO LTD (JP) | 2013-04-24 | — | — | EP | disclosed |
| EP-1995242-B1 | NOVEL 1,2,3,4-TETRAHYDROQUINOXALINE DERIVATIVE HAVING GLUCOCORTICOID RECEPTOR BINDING ACTIVITY | SANTEN PHARMACEUTICAL CO LTD (JP) | 2012-11-07 | — | — | EP | disclosed |
| US-20090111807-A1 | Novel 1,2,3,4-Tetrahydroquinoxaline Derivative Having Glucocorticoid Receptor Binding Activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-04-30 | — | — | US | disclosed |
| US-20090111807-A1 | Novel 1,2,3,4-Tetrahydroquinoxaline Derivative Having Glucocorticoid Receptor Binding Activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-04-30 | — | — | US | disclosed |
| EP-1995242-A1 | NOVEL 1,2,3,4-TETRAHYDROQUINOXALINE DERIVATIVE HAVING GLUCOCORTICOID RECEPTOR BINDING ACTIVITY | Santen Pharmaceutical Co., Ltd (JP) | 2008-11-26 | — | — | EP | disclosed |
| EP-1995242-A1 | NOVEL 1,2,3,4-TETRAHYDROQUINOXALINE DERIVATIVE HAVING GLUCOCORTICOID RECEPTOR BINDING ACTIVITY | Santen Pharmaceutical Co., Ltd (JP) | 2008-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10189796-B2 | [4-(1,3,3-trimethyl-2-oxo-3,4-dihydro-1H-quinoxalin-7-yl)phenoxy]ethyloxy compound or salt thereof | NR3C2, NR3C1, GRK4 | IL6 1589/4885MDM2 4453/4885GRIN1 94/4885 |
| US-10435379-B2 | [4-(1,3,3-trimethyl-2-OXO-3,4-dihydro-1H-quinoxalin-7-yl)phenoxy]ethyloxy compound or salt thereof | NR3C2, NR3C1, MC2R | IL6 1316/4885MDM2 2615/4885GRIN1 128/4885 |
| US-20190106393-A1 | [4-(1,3,3-TRIMETHYL-2-OXO-3,4-DIHYDRO-1H-QUINOXALIN-7-YL)PHENOXY]ETHYLOXY COMPOUND OR SALT THEREOF | NR3C2, NR3C1, MC2R | IL6 1316/4885MDM2 2615/4885GRIN1 128/4885 |
| US-20180244633-A1 | [4-(1,3,3-TRIMETHYL-2-OXO-3,4-DIHYDRO-1H-QUINOXALIN-7-YL)PHENOXY]ETHYLOXY COMPOUND OR SALT THEREOF | NR3C2, NR3C1, GRK4 | IL6 1589/4885MDM2 4453/4885GRIN1 94/4885 |
| US-20090111807-A1 | Novel 1,2,3,4-Tetrahydroquinoxaline Derivative Having Glucocorticoid Receptor Binding Activity | NR3C1, NR3C2, MC2R | IL6 3728/4885MDM2 3959/4885GRIN1 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.